A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

Ipilimumab (IPI) can enhance immunity to the cancer-testis antigen NY-ESO-1. A clinical trial was designed to assess safety, immunogenicity, and clinical responses with IPI + NY-ESO-1 vaccines and effects on the tumor microenvironment (TME). Patients with measurable NY-ESO-1(+) tumors were enrolled...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Slingluff, Craig L., Zarour, Hassane M., Tawbi, Hussein Abdul-Hassan, Kirkwood, John M., Postow, Michael A., Friedlander, Philip, Devoe, Craig E., Gaughan, Elizabeth M., Mauldin, Ileana S., Olson, Walter C., Smith, Kelly T., Macri, Mary J., Ricciardi, Toni, Ryan, Aileen, Venhaus, Ralph, Wolchok, Jedd D.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8007150/
https://ncbi.nlm.nih.gov/pubmed/33796406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1898105
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars